Cochrane Review Group

Haematology

78 systematic reviews in Haematology ask 987 questions. 25.9% have no studies to answer them, 21% rest on very low certainty evidence and 21.6% reach moderate or high certainty.

Reviews

Questions

987

current versions

No studies

25.9%

Moderate or high

21.6%

No studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Haematology

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Intervention NR All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	RR 1 [0.27, 3.7]	3 studies · 451 participants	Very low
Intervention NR Number of participants with any bleeding ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Number of participants with clinically significant bleeding · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	1 study · 84 participants	Very low
Intervention NR Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	3 studies · 431 participants	Very low
Intervention NR All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	1 study · 84 participants	Very low
Intervention NR Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	NR	No studies
Immunomodulatory drug maintenance therapy vs placebo/observation Treatment discontinuation · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane	Risk ratio 0.71 [0.47, 1.05]	2 studies · 400 participants	Very low
Anti‐CD52 mAb maintenance therapy vs observation Overall survival – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane	no estimate extracted	NR	No studies
Anti‐CD52 mAb maintenance therapy vs observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane	no estimate extracted	NR	No studies

Reviews 78

Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission

Mao, C, Fu, XH, et al. · Cochrane Database of Systematic Reviews · 2015

Haematology

Thinnest evidence

Reviews 78

Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission

Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis

The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia

Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma

Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma

A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation

Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation

Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders

The role of additional radiotherapy for primary central nervous system lymphoma

Yoga in addition to standard care for patients with haematological malignancies

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults

Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic hematopoietic stem cell transplantation

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia

Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia

Anthracycline‐containing regimens for treatment of follicular lymphoma in adults

High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma

The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission

Erythropoietin or darbepoetin for patients with cancer

Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation

High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular lymphoma in adults

Alemtuzumab for patients with chronic lymphocytic leukaemia

Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia

Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia